Please assess the completion status of the following clinical trial:

Trial Title: Effects on Ovarian Function of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292003)(COMPLETED)(P05723)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to use COC for at least 6 cycles.~* 18 - 35 years of age at screening.~* Body Mass Index (BMI) of \>/= 17 and \</= 35.~* Good physical and mental health.~* Willing to use condoms as the sole contraceptive method during screening cycle and 1 post-treatment cycle.~* Willing to give informed consent.~Exclusion Criteria:~* Contraindications for contraceptive steroids (general).~* Additional contraindications (renal, hepatic or adrenal insufficiency).~* Breastfeeding.~* Present use (or use within 2 months prior to start of the trial medication) of the following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine, topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole, sex~steroids (other than pre- and post treatment contraceptive method) and herbal remedies containing Hypericum perforatum (St. John's Wort).~* Administration of any other investigational drugs and/or participation in another clinical trial within 2 months prior to the start of the trial medication or during the trial period.~* Abnormal cervical smear at screening, or documentation of an abnormal smear performed within 6 months before screening.~* Clinically relevant abnormal laboratory result at screening as judged by the investigator.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- NOMAC-E2 (Type: EXPERIMENTAL): Nomegestrol Acetate (NOMAC) and Estradiol (E2), 2.5 mg NOMAC and 1.5 mg E2 monophasic combined oral contraceptive
- DRSP-EE (Type: ACTIVE_COMPARATOR): Drospirenone (DRSP) and Ethinyl Estradiol (EE), 3 mg DRSP and 30 mcg EE monophasic combined oral contraceptive

Based on this trial design, predict the completion outcome and termination type (if applicable).